Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95–111 Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R (2018) Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs 27(9):709–720 Razumilava N, Gores GJ (2014) Cholangiocarcinoma. The Lancet 383(9935):2168–2179 Khan SA, Davidson BR, Goldin RD et al (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61(12):1657–1669 Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145(6):1215–1229 Rizvi S, Gores GJ (2017) Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol 67(3):632–644 Krasinskas AM (2018) Cholangiocarcinoma. Surg Pathol Clin 11(2):403–429 Joo I, Lee JM, Yoon JH (2018) Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology 288(1):7–13 Mertens JC, Rizvi S, Gores GJ (2018) Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864:1454–1460 Everhart JE, Ruhl CE (2009) Burden of digestive diseases in the United States part iii: liver, biliary tract, and pancreas. Gastroenterology 136(4):1134–1144 Lamarca A, Barriuso J, McNamara MG, Valle JW (2020) Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol 73(1):170–185 Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS (2016) Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 122(9):1349–1369 Oliveira IS, Kilcoyne A, Everett JM, Mino-Kenudson M, Harisinghani MG, Ganesan K (2017) Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol (NY) 42(6):1637–1649 Cameron K, Golan S, Simpson W et al (2011) Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging 36(4):463–471 Cui X-Y, Chen H-W (2010) Role of diffusion-weighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma. World J Gastroenterol 16(25):3196–3201 Cui X-Y, Chen H-W, Cai S et al (2012) Diffusion-weighted MR imaging for detection of extrahepatic cholangiocarcinoma. Eur J Radiol 81(11):2961–2965 Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H (2016) Role of 18F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med 41(1):1–7 Yoh T, Seo S, Morino K et al (2019) Reappraisal of prognostic impact of tumor SUVmax by F-FDG-PET/CT in intrahepatic cholangiocarcinoma. World J Surg 43(5):1323–1331 Liu XF, Tang K, Sui LL, Xu G (2014) Cholangiocarcinoma: present status and molecular aspects of diagnosis. Oncol Res 22(4):177–183 Njei B, McCarty TR, Varadarajulu S, Navaneethan U (2016) Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther 44(11–12):1139–1151 Breitenstein S, Apestegui C, Clavien PA (2008) Positron emission tomography (PET) for cholangiocarcinoma. HPB (Oxford) 10(2):120–121 Hennedige TP, Neo WT, Venkatesh SK (2014) Imaging of malignancies of the biliary tract- an update. Cancer Imaging 14:14 Mar WA, Shon AM, Lu Y et al (2016) Imaging spectrum of cholangiocarcinoma: role in diagnosis, staging, and posttreatment evaluation. Abdom Radiol (NY) 41(3):553–567 Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD (2008) Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48(4):1106–1117 Saluja SS, Sharma R, Pal S, Sahni P, Chattopadhyay TK (2007) Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study. HPB (Oxford) 9(5):373–382 Anderson CJ, Lewis JS (2017) Current status and future challenges for molecular imaging. Philos Trans A Math Phys Eng Sci.375(2107). Cassidy PJ, Radda GK (2005) Molecular imaging perspectives. J R Soc Interface 2(3):133–144 England CG, Hernandez R, Eddine SB, Cai W (2016) Molecular imaging of pancreatic cancer with antibodies. Mol Pharm 13(1):8–24 Kluge R, Schmidt F, Caca K et al (2001) Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33(5):1029–1035 Moon CM, Bang S, Chung JB et al (2008) Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 23(5):759–765 Corvera CU, Blumgart LH, Akhurst T et al (2008) 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206(1):57–65 Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D (2004) Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8(1):90–97 Li J, Kuehl H, Grabellus F et al (2008) Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 98(6):438–443 Smith WL, Urade Y, Jakobsson PJ (2011) Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 111(10):5821–5865 Chang CW, Yeh CN, Chung YH et al (2018) Synthesis and evaluation of ortho-[(18)F] fluorocelecoxib for COX-2 cholangiocarcinoma imaging. Drug Des Devel Ther 12:1467–1478 Sirica AE (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41(1):5–15 Huang HL, Yeh CN, Lee WY et al (2013) [123I]Iodooctyl fenbufen amide as a SPECT tracer for imaging tumors that over-express COX enzymes. Biomaterials 34(13):3355–3365 Labib PL, Goodchild G, Pereira SP (2019) Molecular pathogenesis of cholangiocarcinoma. BMC Cancer 19(1):185 Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C, Pawlik TM (2017) Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol 26(2):125–137 Borad MJ, Champion MD, Egan JB et al (2014) Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 10(2):e1004135 Walenkamp AME, Lapa C, Herrmann K, Wester HJ (2017) CXCR4 ligands: the next big hit? J Nucl Med 58(Suppl 2):77S-82S Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49(1):219–230 Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ (2011) PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem 6(10):1789–1791 Gourni E, Demmer O, Schottelius M et al (2011) PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 52(11):1803–1810 Kircher M, Herhaus P, Schottelius M et al (2018) CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med 32(8):503–511 Werner RA, Weich A, Schirbel A et al (2016) Intraindividual tumor heterogeneity in NET – Further insight by C-X-C motif chemokine receptor 4-directed imaging. Eur J Nucl Med Mol Imaging 44(3):553–554 Werner RA, Kircher S, Higuchi T et al (2019) CXCR4-directed imaging in solid tumors. Front Oncol 9:770 Detsky JS, Keith J, Conklin J et al (2017) Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology. J Neurooncol 134(2):433–441 Kim JE, Lee JM, Kim SH et al (2010) Differentiation of intraductal growing-type cholangiocarcinomas from nodular-type cholangiocarcinomas at biliary MR imaging with MR cholangiography. Radiology 257(2):364–372 Zhang H, Zhu J, Ke F et al (2015) Radiological imaging for assessing the respectability of hilar cholangiocarcinoma: a systematic review and meta-analysis. Biomed Res Int 2015:497942 Feng S-T, Wu L, Cai H et al (2015) Cholangiocarcinoma: spectrum of appearances on Gd-EOB-DTPA-enhanced MR imaging and the effect of biliary function on signal intensity. BMC Cancer 15:38 Taruno K, Kurita T, Kuwahata A et al (2019) Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparticles and a novel handheld magnetic probe. J Surg Oncol 120(8):1391–1396 Kim MJ, Kim JH, Lim JS et al (2004) Detection and characterization of focal hepatic lesions: mangafodipir vs superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Resonan Imaging 20(4):612–621 Maurea S, Mainenti PP, Tambasco A et al (2014) Diagnostic accuracy of MR imaging to identify and characterize focal liver lesions: comparison between gadolinium and superparamagnetic iron oxide contrast media. Quant Imaging Med Surg 4(3):181–189 Polakova K, Mocikova I, Purova D et al (2016) Magnetic resonance cholangiopancreatography (MRCP) using new negative per-oral contrast agent based on superparamagnetic iron oxide nanoparticles for extrahepatic biliary duct visualization in liver cirrhosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 160(4):512–517 Yuan Y, He Y, Bo R et al (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10(46):21634–21639 Reichardt W, Hu-Lowe D, Torres D, Weissleder R, Bogdanov A Jr (2005) Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model. Neoplasia 7(9):847–853 Jun EJ, Song HY, Park JH et al (2018) In vivo fluorescence microendoscopic monitoring of stent-induced fibroblast cell proliferation in an esophageal mouse model. J Vasc Interv Radiol 29(12):1756–1763 Mezzanotte L, van ’t Root M, Karatas H, Goun EA, Lowik C (2017) In vivo molecular bioluminescence imaging: new tools and applications. Trends Biotechnol 35(7):640–652 Wells RG (2016) Instrumentation in molecular imaging. J Nucl Cardiol 23(6):1343–1347 Dubow M, Tatman PD, Shah RJ (2018) Individual probe based confocal laser endomicroscopy criteria in the analysis of indeterminate biliary strictures. Scand J Gastroenterol 53(10–11):1358–1363 Yokoyama H, Sasaki A, Yoshizawa T, Kijima H, Hakamada K, Yamada K (2016) Imaging hamster model of bile duct cancer in vivo using fluorescent L-glucose derivatives. Hum Cell 29(3):111–121 Wani S, Shah RJ (2013) Probe-based confocal laser endomicroscopy for the diagnosis of indeterminate biliary strictures. Curr Opin Gastroenterol 29(3):319–323 Sasaki A, Nagatomo K, Ono K et al (2016) Uptake of a fluorescent L-glucose derivative 2-NBDLG into three-dimensionally accumulating insulinoma cells in a phloretin-sensitive manner. Hum Cell 29(1):37–45 Yamada K, Saito M, Matsuoka H, Inagaki N (2007) A real-time method of imaging glucose uptake in single, living mammalian cells. Nat Protoc 2(3):753–762 Thekkek N, Maru DM, Polydorides AD, Bhutani MS, Anandasabapathy S, Richards-Kortum R (2011) Pre-clinical evaluation of fluorescent deoxyglucose as a topical contrast agent for the detection of Barrett’s-associated neoplasia during confocal imaging. Technol Cancer Res Treat 10(5):431–441 Zhang C, Kimura R, Abou-Elkacem L, Levi J, Xu L, Gambhir SS (2016) A cystine knot peptide targeting integrin alphavbeta6 for photoacoustic and fluorescence imaging of tumors in living subjects. J Nucl Med 57(10):1629–1634 Alkhawaldeh K, Faltten S, Biersack H-J, Ezziddin S (2011) The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis. Clin Nucl Med 36(10):879–883 Wakabayashi H, Akamoto S, Yachida S et al (2005) Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol 31(10):1175–1179 Kim JY, Kim M-H, Lee TY et al (2008) Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 103(5):1145–1151 Ferrone C, Goyal L, Qadan M et al (2020) Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 47(8):1871–1884 Catalano OA, Rosen BR, Sahani DV et al (2013) Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology 269(3):857–869 Catalano OA, Nicolai E, Rosen BR et al (2015) Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer 112(9):1452–1460 Yang X (2010) Interventional molecular imaging. Radiology 254(3):651–654 Takakusagi Y, Naz S, Takakusagi K et al (2018) A multimodal molecular imaging study evaluates pharmacological alteration of the tumor microenvironment to improve radiation response. Cancer Res 78(24):6828–6837 Zhang F, Bai Z, Shi Y, Wang J, Li Y, Yang X (2015) Interventional MRI-guided local delivery of agents into swine bile duct walls using MR-compatible needle-integrated balloon catheter system. NMR Biomed 28(6):679–684 Zhang F, Le T, Wu X et al (2014) Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging–preclinical study. Radiology 270(2):400–408 Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17(5):545–580